Enjoy complimentary customisation on priority with our Enterprise License!
The autologous cell therapy market share is expected to increase by USD 4.11 billion from 2020 to 2025, and the market's growth momentum will accelerate at a CAGR of 14.16%.
This autologous cell therapy market research report provides valuable insights on the post COVID-19 impact on the market, which will help companies evaluate their business approaches. Furthermore, this report extensively covers autologous cell therapy market segmentation by product (autologous stem cell therapy and autologous cellular immunotherapies) and geography (North America, Europe, APAC, MEA, and South America). The autologous cell therapy market report also offers information on several market vendors, including Bayer AG, Brainstorm Cell Therapeutics Inc., Daiichi Sankyo Co. Ltd., FUJIFILM Holdings Corp., Holostem Terapie Avanzate Srl, Osiris Therapeutics Inc., Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Sumitomo Chemical Co. Ltd., and Vericel Corp. among others.
Download the Free Report Sample to Unlock the Autologous Cell Therapy Market Size for the Forecast Period and Other Important Statistics
The increasing demand for effective drugs for cardiac and degenerative disorders is notably driving the autologous cell therapy market growth, although factors such as critical ethical challenges with respect to stem cell research may impede the market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the autologous cell therapy industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.
Key Autologous Cell Therapy Market Driver
The increasing demand for effective drugs for cardiac and degenerative disorders is a major factor driving the global autologous cell therapy market share growth. There has been an increased demand for providing effective drugs for cardiac and degenerative disorders globally. Prior to the advent of autologous cell therapies, there was no effective drug to repair a damaged heart. The discovery of possible cardiac autologous cells opened new possibilities for repairing damaged cardiac tissue caused by acute myocardial infarction or coronary artery disease. There are approximately 19 product candidates being developed for the treatment of cardiac disorders, with eight in Phase III and six in Phase II development stages. Some of the companies that are developing these drugs include Shire, Athersys, Japan Regenerative Medicine, MyoCell, and Celyad. Mesoblast is developing MPC-150-IM, a Phase III candidate for the treatment of advanced and end-stage chronic heart failure. Also, in July 2019, Bayer AG provided about $250 million to Century Therapeutics for the development of next-generation immune-oncology therapeutics. In addition, Shire has been developing autologous stem cell therapies for chronic myocardial ischemia. These products are expected to be launched during the forecast period and will have a substantial impact on market growth.
Key Autologous Cell Therapy Market Trend
The increasing M&A activities is another factor supporting the global autologous cell therapy market share growth. M&A activities have the potential to enable vendors to explore additional opportunities without incurring a huge financial burden. Such alliances for product development and product commercialization provide vendors with multiple benefits, such as cost containment, extended product lines, and increased geographical reach. This is expected to support the growth of the market during the forecast period.
Key Autologous Cell Therapy Market Challenge
The critical ethical challenges with respect to stem cell research will be a major challenge for the global autologous cell therapy market share growth during the forecast period. Over the years, there has been a continuous debate over ethical issues related to stem cell therapy. Embryonic stem cell development is continuously debated by scientists and policymakers. The use of human embryonic stem cells in research has always concerned decision-makers and the scientific fraternity. Some of the issues include the cloning of embryonic stem cells and the destruction of embryos to create cell lines. Moreover, concerns regarding safety, scientific purity, and consent to the use of human embryonic stem cell lines for research purposes have always been points of concern. Also, stem cell therapy requires experiments and clinical trials on animals. With growing ethical concerns globally, animal testing must be regulated by government agencies to minimize the use of animals in research. Therefore, the presence of ethical issues may act as a hindrance to the ongoing research in stem cell therapy and may inhibit market growth during the forecast period.
This autologous cell therapy market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2021-2025.
Technavio categorizes the global autologous cell therapy market as part of the global pharmaceutical market. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the autologous cell therapy market during the forecast period.
The report analyzes the market's competitive landscape and offers information on several market vendors, including:
This statistical study of the autologous cell therapy market encompasses successful business strategies deployed by the key vendors. The autologous cell therapy market is fragmented and the vendors are deploying organic and inorganic growth strategies to compete in the market.
To make the most of the opportunities and recover from post-COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.
The autologous cell therapy market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.
Our report provides extensive information on the value chain analysis for the autologous cell therapy market, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chain is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.
The value chain of the global pharmaceutical market includes the following core components:
The report has further elucidated other innovative approaches being followed by manufacturers to ensure a sustainable market presence.
Executive Summary
Market Landscape
Market Sizing
Five Forces Analysis
Market Segmentation by Product
Customer landscape
Geographic Landscape
Vendor Landscape
Vendor Analysis
Appendix
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.
Get the report (PDF) sent to your email within minutes.